Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuanglong Baoxin
- Development stage
- Unknown
- Lead developer
- Xiangxue Pharmaceutical
- Administration
- Oral
01
Overview
Shuanglong Baoxin is a traditional Chinese medicine (TCM) formulation developed by Xiangxue Pharmaceutical for the treatment of coronary heart disease. It is currently in Phase 1 clinical development. As a multi-component herbal therapy, it is designed to address cardiovascular symptoms associated with coronary heart disease, although its specific molecular targets and pharmacological mechanisms have not been detailed in public clinical disclosures. The drug is formulated as an oral tablet.
- Brand names
- Shuanglong Baoxin Tablet
- Other names
- 双龙保心片
02
Targets
ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on Shuanglong Baoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shuanglong Baoxin.